Introduction {#Sec1}
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COVID-19 is the illness caused by infection with the novel coronavirus SARS-CoV-2. SARS-CoV-2 first emerged in China in December 2019 and shortly thereafter spread worldwide. In adults, the most common presenting symptoms are fever (76--91%), cough (63--65%), fatigue (38.5--50%), dyspnea (14--44%), anorexia (12--24%), diarrhea (15--28%), and myalgia (11--22%) \[[@CR1]--[@CR3]\]. In children, fever (36--41.5%), cough (19--48.5%), and diarrhea (9--12%) are most common \[[@CR4]--[@CR6]\]. Although myalgias are common in adults, no studies in children noted the presence of myalgias \[[@CR4], [@CR5]\]. There have been a few reported cases of COVID-19-associated rhabdomyolysis in adults, but no such cases have been reported in children \[[@CR7]--[@CR10]\].

Rhabdomyolysis is defined as the breakdown of skeletal muscle leading to leaking of muscle contents into the extracellular fluid \[[@CR11]\]. Although there is no official consensus, it is usually defined by a serum creatine kinase (CK) of \> 1000 U/L, which is five times the upper limit of normal \[[@CR11]\]. Patients with rhabdomyolysis can be asymptomatic or present with myalgia, weakness, myoglobinuria with dark urine, significant electrolyte imbalance, and acute kidney injury \[[@CR11]\]. Rhabdomyolysis in children is commonly caused by viral myositis, trauma, connective tissue disorders, and drug overdose \[[@CR11]\]. The most common viral causes of rhabdomyolysis are influenza A and B viruses followed by HIV and enteroviruses \[[@CR12]\]. Rarely, other viruses have been reported to cause rhabdomyolysis, including coronaviruses such as SARS-CoV-1 \[[@CR12], [@CR13]\]. Here we present a case of pediatric COVID-19-associated rhabdomyolysis.

Case report {#Sec2}
===========

A 16-year-old boy with autism spectrum disorder, attention deficit hyperactivity disorder, morbid obesity, obstructive sleep apnea, and eczema presented with fever, myalgias, shortness of breath with exertion, and dark-colored urine. Five days prior to admission, he began to feel fatigue. Four days prior to admission, he noted myalgias of his arms, legs, abdomen, and back, as well as mild shortness of breath on exertion. One day prior to admission, he was evaluated by an urgent care center where he was febrile to 38.9 °C. He denied any congestion, rhinorrhea, anosmia, inability to taste, dysuria, nausea, vomiting, or diarrhea. Of note, he was found to have cola-colored urine. When asked about the duration of dark urine, he stated it had been occurring for 2 days, but his mother was not certain that his estimation was accurate given his autism spectrum disorder. He took acetaminophen intermittently in the days prior and denied taking any non-steroidal anti-inflammatory agents. The family history was significant for hypertension and type 2 diabetes mellitus.

In the emergency department, vital signs were as follows: maximum temperature of 37.8 °C, heart rate of 122 BPM, respiratory rate of 18--20 breaths/min, and oxygen saturation of 99--100% on room air. His blood pressure was initially elevated at 133/87 mmHg but lowered to normal range without intervention. He was well appearing on exam, with the only focal findings being pharyngeal erythema and diffuse abdominal pain. Initial laboratory work-up revealed a slight elevation in white blood cell count at 10.74 K/uL and slightly low platelets at 138 K/uL. Serum creatinine was normal for age at 0.89 mg/dL and electrolytes were within normal range. AST and ALT were elevated at 839 U/L and 157 U/L, respectively, and GGT was normal at 37 U/L. Urinalysis showed a pH of 6.0, large blood with 11--25 RBC/HPF and 6--10 WBC/HPF. Random urine protein-to-creatinine ratio was elevated at 0.81 mg/mg. Kidney ultrasound with Doppler and abdominal ultrasound were normal. Respiratory pathogen PCR panel was negative, but COVID-19 PCR was positive. Hepatitis and cytomegalovirus serologies were negative. Epstein-Barr serologies were indicative of resolved past infection. Antistreptolysin O screen was not elevated and throat culture was negative. C3 and C4 were normal. Antinuclear antibody, double-stranded DNA, and anti-glomerular basement membrane IgG results were all negative. The patient's CK level was 427,656 U/L.

On admission, vital signs were as follows: weight 162 kg, body mass index 54.3 kg/m^2^ (\> 99th percentile), blood pressure 122/72 mmHg, temperature 37.7 °C, heart rate 110 BPM, respiratory rate 20 breaths/min, and oxygen saturation of 98--100% on room air. Physical exam was notable for obesity, acanthosis nigricans, and tenderness to palpation of distal anterior lower legs. Repeat CK was 296,396 U/L. Urine myoglobin was sent but did not result. His sodium decreased to 130 mmol/L, albumin decreased to 3.2 g/dL, and creatinine remained normal for age at 0.68 mg/dL. Ferritin was normal, but procalcitonin (0.22 ng/mL), lactate dehydrogenase (2184 U/L), C-reactive protein (24.9 mg/L), and troponin (58 ng/L) were elevated. Echocardiogram was normal. Toxicology screen was negative. Incidentally, hemoglobin A1c was found to be elevated in the diabetic range at 8.2%. He was given a 1000 mL normal saline bolus and started on isotonic intravenous fluids containing sodium bicarbonate and potassium chloride at 200 mL/h.

On hospital day 2, CK was down to 108,059 U/L. Sodium and albumin normalized. Urine pH was \> 7.0. On hospital day 4, he continued to have significant myalgias requiring acetaminophen and morphine. His fluids were reduced to 100 mL/h as his CK had decreased to 53,977 U/L, and his serum creatinine remained normal. However, on hospital day 6, his CK doubled from the previous day to 159,675 U/L, and his fluids were increased back to 200 mL/h. His blood pressures became persistently elevated and amlodipine 5 mg daily was initiated. Starting on hospital day 7, he no longer complained of myalgias and did not require further analgesic medications. On hospital day 9, his CK was 36,294 U/L and his urine was negative for blood, so the fluid rate was decreased. Urine myoglobin was resent and was elevated at 45 mcg/L. On hospital day 11, his CK was 11,732 U/L and urine remained negative for blood. His fluids were stopped along with his amlodipine as his blood pressures normalized. He was discharged on hospital day 12 with a CK of 6526 U/L. The CK trend is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Creatine kinase trend over time

Discussion {#Sec3}
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Herein, we present a case of severe rhabdomyolysis without acute kidney injury that was associated with COVID-19 infection in a pediatric patient. To our knowledge, no cases of COVID-19-associated rhabdomyolysis have been previously reported in children or adolescents.

A few adult cases have been reported recently, none of which had CK levels nearly as high as our patient's. In a series of 1099 patients with COVID-19 in China, 2 patients were diagnosed with rhabdomyolysis. The ages of these patients were not specified, but of all the study patients, \< 1% of patients were less than 15-years-old \[[@CR10]\]. Another group in China analyzed the autopsies of 26 adult patients with COVID-19 and found pigmented casts associated with high CK levels in 3 patients \[[@CR7]\]. One case of COVID-19-associated rhabdomyolysis was reported in a 60-year-old male in Wuhan, China, with a maximum CK of 17,434 U/L without any subsequent acute kidney injury \[[@CR14]\]. The only case of COVID-19-associated rhabdomyolysis reported in the USA was of an 88-year-old male with a maximum CK of 13,581 U/L with subsequent development of mild acute kidney injury that resolved with intravenous fluid administration \[[@CR8]\].

Several studies from China reported patients with elevated CK levels without development of rhabdomyolysis. In a study of 95 adults, 12 had CK levels 200--400 U/L, 9 had levels 400--600 U/L, and 7 had levels \> 600 U/L \[[@CR15]\]. In a study of 91 adults, 14 had CK levels \> 190 U/L and 15 had myalgias, but there is no indication if those with elevated CK were those with myalgias \[[@CR3]\]. In a study of 161 adults, 17 had CK levels \> 190 U/L and 18 had myalgias, but there is no indication if those elevated CK were those with myalgias \[[@CR1]\]. The only pediatric study that assessed CK levels involved 32 children and found that no patients had rhabdomyolysis and only one patient had CK \> 170 U/L \[[@CR4]\].

In general, the pathogenesis of different types of viral rhabdomyolysis has been debated and includes direct invasion of the muscle by virus, cytokine storm resulting in muscle damage, and muscle injury by circulating viral toxins. Chen et al. postulated that SARS-CoV-1-associated rhabdomyolysis was secondary to cytokine storm rather than direct viral invasion due to the presence of high inflammatory markers and the lack of viral particles on muscle biopsies \[[@CR13]\]. There are no reports of muscle biopsies in patients with COVID-19-associated rhabdomyolysis, but similar to SARS, COVID-19 is also associated with high inflammatory markers. This may indicate that rhabdomyolysis in COVID-19 could be cytokine-mediated.

In conclusion, this case illustrates a pediatric patient who presented with myalgia and severe rhabdomyolysis in the setting of COVID-19 infection. Rhabdomyolysis and elevated CK may be under-recognized complications of COVID-19 in pediatrics. Given this pediatric case of COVID-19-associated rhabdomyolysis and the multiple reports in adults, pediatric clinicians should be aware of this complication. We recommend checking CK levels in pediatric patients presenting with myalgia, especially those with urinary changes or acute kidney injury. When treating rhabdomyolysis, aggressive fluid administration is important to prevent acute kidney injury. However, it is especially important to monitor for signs of heart failure and pulmonary edema as these complications can occur in COVID-19 patients even without aggressive fluid administration.
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